NO20072705L - Alfa-tymosinpeptider som cancervaksineadjuvanser - Google Patents

Alfa-tymosinpeptider som cancervaksineadjuvanser

Info

Publication number
NO20072705L
NO20072705L NO20072705A NO20072705A NO20072705L NO 20072705 L NO20072705 L NO 20072705L NO 20072705 A NO20072705 A NO 20072705A NO 20072705 A NO20072705 A NO 20072705A NO 20072705 L NO20072705 L NO 20072705L
Authority
NO
Norway
Prior art keywords
cancer vaccine
alpha
subject
vaccine adjuvants
thymosin peptides
Prior art date
Application number
NO20072705A
Other languages
English (en)
Norwegian (no)
Inventor
Alfred R Rudolph
Gustavo Antonio Moviglia
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20072705L publication Critical patent/NO20072705L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20072705A 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser NO20072705L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
NO20072705L true NO20072705L (no) 2007-09-05

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072705A NO20072705L (no) 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser

Country Status (15)

Country Link
US (1) US20100092499A1 (cg-RX-API-DMAC7.html)
EP (1) EP1835931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008523067A (cg-RX-API-DMAC7.html)
KR (1) KR20070086663A (cg-RX-API-DMAC7.html)
CN (1) CN101072582B (cg-RX-API-DMAC7.html)
AU (1) AU2005314271B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588685A1 (cg-RX-API-DMAC7.html)
EA (1) EA015510B1 (cg-RX-API-DMAC7.html)
IL (1) IL183264A (cg-RX-API-DMAC7.html)
MX (1) MX2007006717A (cg-RX-API-DMAC7.html)
NO (1) NO20072705L (cg-RX-API-DMAC7.html)
NZ (1) NZ555571A (cg-RX-API-DMAC7.html)
UA (1) UA90493C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006062917A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
US20150031617A1 (en) * 2012-03-08 2015-01-29 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CZ20014718A3 (cs) * 1999-06-30 2003-01-15 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
DE60224435T2 (de) * 2001-10-26 2009-01-02 Rhode Island Hospital Thymosin-augmentation bei genetischer immunisierung
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
MXPA05000078A (es) * 2002-06-28 2005-04-11 Sciclone Pharmaceuticals Inc Metodo para sobre-regular la expresion de antigeno tumoral utilizando timalfasina, y composiciones y usos.
AU2004226403B2 (en) * 2003-03-28 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Also Published As

Publication number Publication date
AU2005314271A1 (en) 2006-06-15
UA90493C2 (ru) 2010-05-11
EP1835931A4 (en) 2008-12-17
KR20070086663A (ko) 2007-08-27
JP2008523067A (ja) 2008-07-03
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16
CN101072582A (zh) 2007-11-14
EP1835931A2 (en) 2007-09-26
CA2588685A1 (en) 2006-06-15
MX2007006717A (es) 2007-08-06
IL183264A (en) 2010-12-30
CN101072582B (zh) 2012-06-27
EA200701166A1 (ru) 2008-02-28
NZ555571A (en) 2009-02-28
IL183264A0 (en) 2007-09-20
AU2005314271B2 (en) 2011-06-16
BRPI0518571A2 (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
MX2009009342A (es) Metodo novedoso y composiciones.
PE20121393A1 (es) Analogo peptidico de oxintomodulina
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
NZ534919A (en) Bioactive keratin peptides
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
RU2013131089A (ru) Пептиды тем8 и содержащие их вакцины
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
PL1879612T3 (pl) Zastosowanie peptydów natywnych i ich zoptymalizowanych pochodnych do szczepienia
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2011038397A3 (en) Peptide adjuvants, vaccines, and methods of use
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
WO2003093298A3 (en) Immunogenic peptides
WO2012015979A3 (en) Hmgb1-derived peptides enhance immune response to antigens
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
NO20061542L (no) P185neu-Kodende DNA samt terapeutiske anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application